Member Info for equitrder

I don't know either...I do know Deutsche Bank were trying to flog Deutsche Post Bank and could find a bid.. Amazing and SNAP is worth 20 billion.

The pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, yesterday announced the completion of discussions with the Food and Drug Administration (‘FDA’) and European Medicines Agency (‘EMA’) regarding the design of its pivotal phase 3 clinical trial for AP101. This molecule is a potential treatment for Epidermolysis Bullosa (‘EB’). EB is a rare genetic skin disorder that leads to exceptionally fragile skin and children with the disorder are often referred to as “Butterfly Children”. The global market for a treatment in EB is estimated to be in excess of EUR 1.3 billion. With regulatory authority discussions now completed with FDA and EMA and the design of the clinical trial established, Amryt is on track to commence the phase 3 trial at the end of March. Amryt has also agreed to conduct some further non-clinical studies in parallel with this phase 3 study. INC Research has been appointed as the contract research organisation for the phase 3 study, and approximately 30 clinical trial sites in 15 countries have already been pre-qualified. Adult and paediatric patients with EB will be enrolled into a randomised double blind placebo controlled trial. A total of 164 evaluable patients will be treated for a 90-day blinded period. The proportion of patients with completely healed target wounds within 45 days will be evaluated as the primary endpoint. Secondary endpoints include the time to achieve wound healing and changes in pain and pruritus (or itch). An important component of the phase 3 study is an independent data monitoring committee that will conduct an un-blinded interim efficacy analysis after 50% enrolment. The potential outcomes of this interim analysis include continuation of the study unchanged, discontinuation of the study for futility, or an increase in the number of patients in the study to preserve adequate statistical power. Our view: This is very positive news! Reaching this critical development milestone is an important step forward for Amryt. AP101 received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. But agreement with the regulatory authorities for its phase 3 study in EB was a precursor to commencing its pivotal study, which it now expect will enrol its first patients in the coming weeks. There remains substantial unmet need for drugs which can address the symptoms and significant progress can now be made toward a potential treatment this review. Working with INC Research, Amryt believes an adaptive approach to study sample size will help to ensure that it achieves a reliable assessment of the potential benefit of this new skin healing treatment for the orphan designated disease. Having patent grants in the US and in Europe, as well as other territories including Japan, Canada and Australia, the Board estimates its global EB market opportunity to be in excess of EUR 1.3 billio

If UK is finished it certainly isn't showing up in the property market. Have a friend living in a pretty good area of London,got a knock on his door Sunday and was offered 28% more than he figured his house was worth on the spot. (With a bank approval letter for said sum)

T5 Oil & Gas to launch IPO in drive to build $1bn company Exploration firm backed by industry heavy-hitters aims to list in Dublin and London, writes Gavin McLoughlin March 5 2017 2:30 AM Shareholders in T5 Oil & Gas have been told the company plans to float on the Irish & London Stock Exchanges in April, the Sunday Independent has learned. The oil and gas exploration firm has hired Davy Stockbrokers and London-based boutique investment bank Hannam & Partners to advise it on the transaction, which will see it list shares on the Alternative Investment Market in London and the Enterprise Securities Market in Dublin. The company's stated aim is to become a listed, billion-dollar company and it is backed by a number of industry heavyweights. T5 has written to shareholders, saying it will be seeking their approval for the transaction shortly. It hopes to capitalise on the recent improvement in oil and gas industry conditions. The London-based firm was set up by a group of Tullow Oil veterans. It is run by executive chairman Pat Plunkett, who is also the chairman of Providence Resources. Plunkett was the chairman of Tullow Oil from 2000 to 2011, during which time the company went from a market cap of £275m to over £12bn.He was a founder of Riada Stockbrokers, which was later bought by Dutch bank ABN-AMRO. The company declined to comment. Its website says it is "in the early stages of building a publicly-listed billion-dollar Africa and Middle East E&P company - creating long-term value for our stakeholders". The amount of money raised - and subsequently the valuation assigned to the company - will be determined by market conditions, as will the precise timing of the company's listing. T5 owns 90pc of an exploration block in Senegal in West Africa. Funds raised in the flotation would help with work on that asset as well as the pursuit of further acquisitions. Previously it considered a bid for Egyptian production assets owned by Petroceltic, which put itself up for sale at the end of 2015 after running out of cash. It will be the first float in Dublin this year. The last firm to list on the Irish Stock Exchange was venture capital provider Draper Esprit, which raised €102m when it went public in June of last year. Apart from Plunkett, other ex-Tullow figures involved in the company include exploration director Gerry Sheehan, previously an international exploration manager at Tullow. Matthew O'Donoghue, a former director of international operations at Tullow, is on T5's board, as is former Tullow managing director for Africa Andrew Windham. Sunday Indo Business

Paddy Irishman is derogatory! It's an ethnic slur..

With a name like that he deserves to be ****ged!

Glad to see the results in the north.The DUP homophobes and bigots will have to conform.

Disgraceful!!!

I think your way off... Theresa May is obviously a woman not ageing very well Arlene Foster is repulsive on every level..

It took over 150 mil shares to get .2275 to .235 and less that 2.5 million to get back to .2275..

Torquay... Copy and paste. (:

Will they close its.23 or .235?

Very disappointing..

And u don't think FF are worse hypocrits? I hope SDLP UUP and Alliance make ground and push those DUP BIGOTS to the kerb.

Real good volume on the ISE

But worst performer in the banking index..

Good call.. Only problem is the volume is anemic

Wow looks at the trades... 1 shares traded at the bid all afternoon

Still don't know how BIR.IR finished lower on the day... Amazing

Tapping the bid with tiny trades 09:02:04 0.2225 9,192 2,045 08:59:21 0.2225 3,197 711.33 08:58:19 0.2225 3,390 754.28 08:57:28 0.2225 3,473 772.74 08:56:06 0.2225 3,595 799.89 08:55:31 0.2225 3,719 827.48 08:54:04 0.2225 3,672 817.02 08:53:34 0.2225 3,800 845.50 08:52:11 0.2225 3,924 873.09 08:51:41 0.2225 4,061 903.57 08:50:04 0.2225 4,429 985.45 08:49:16 0.2225 4,649 1,034 08:48:23 0.2225 4,812 1,071 08:47:39 0.224 54,000 12.10k 08:47:04 0.2225 4,977 1,107 08:46:29 0.2225 5,128 1,141 08:45:03 0.2225 5,305 1,180 08:44:20 0.2225 5,672 1,262 08:43:28 0.2225 5,927 1,319 08:42:15 0.2225 6,060 1,348 08:41:12 0.2225 6,227 1,386 08:40:42 0.2225 6,400 1,424 08:39:28 0.2225 13,606 3,027